Many EU countries don't have the infrastructure to support the Mabs. Several health systems have declined to pay for the Mabs, so the AD need is still unmet in many countries.
And the EMA has ZERO additional AD drug applications in hand and none of us here see any in the foreseeable future.
For European AD patients and their caregivers Blarcamasine is the only hope for that foreseeable future and let’s assume the CHMP doesn’t let them down.
Market Data 
Markets 
AI
